Dangerous Blood Thinner Xarelto Helps Bayer Earn Billions Despite Mounting Reports of Bleeding and Death

Bloomberg reported that Bayer AG’s 3rd Quarter earnings rose to $2.7 Billion led by sales of its dangerous blood thinner Xarelto. http://www.bloomberg.com/news/2013-10-31/bayer-third-quarter-earnings-rise-on-new-medicines.html. We previousy explained that Xarelto is dangerous because there is no antidote to stop the bleeding once the event occurs. If someone suffers a puncture wound while on Xarelto from an accident as simple as stepping on a nail, there is the very real possibility that they could bleed to death in an emergency room because there may be no way to stop the bleeding. Pradaxa, another hazardous blood thinner in the same class as Xarelto, carries the same life-threatening side effects because the lack of an antidote. Warfarin, on the other hand, does not pose the same risk of bleeding to death because it has an antidote, Vitamin K, which can stop the bleeding event. It’s our understanding that Bayer is working with Johnson & Johnson to develop and antidote for Xarelto. Until an effective antidote is developed, we consider Xarelto a defective and very dangerous drug. If you or a loved one suffered a serious bleeding event or death while on Xarelto, please feel free to contact the Levensten Law Firm to discuss your legal rights to compensation for your injuries.